OptimizeRx Corporation reaffirmed financial guidance for the year 2022. The company is reaffirming its full year financial outlook for 2022 and continues to expect net revenues of $80 million to $85 million, representing year-over-year growth of 31% to 39%, respectively.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.12 USD | -1.51% | -7.79% | -22.29% |
06-05 | Transcript : OptimizeRx Corporation - Shareholder/Analyst Call | |
05-14 | Transcript : OptimizeRx Corporation, Q1 2024 Earnings Call, May 14, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.29% | 203M | |
+27.66% | 443B | |
+31.75% | 276B | |
+12.57% | 145B | |
+7.73% | 93.11B | |
+24.44% | 90.17B | |
+64.02% | 61.13B | |
+14.54% | 46.32B | |
+23.05% | 35.73B | |
-12.79% | 31.13B |
- Stock Market
- Equities
- OPRX Stock
- News OptimizeRx Corporation
- OptimizeRx Corporation Reaffirms Financial Guidance for the Year 2022